升荣胶囊联合化疗治疗中晚期非小细胞肺癌

The rapeutic effect of Shengrong Capsule with combinations of chemotherapy in treatment of advanced non-small-cell lung cancer

目的 观察升荣胶囊联合化疗治疗对一线治疗无效的非小细胞肺癌(NSCLC)的疗效及不良反应.方法 应用升荣胶囊联合其他常用化疗药物组成的联合化疗方案治疗NSCLC 68例,观察其疗效与不良反应.结果 试验组近期缓解率89.2%,对照组70.1%;症状改善率:试验组81.5%,对照组为53.9%;白细胞下降率治疗组为29.0%,对照组为41.9%;血小板下降率治疗组为29.0%,对照组为48.4%;两组差异均有统计学意义(P＜0.05).结论 升荣胶囊与化疗药物联合治疗NSCLC能提高疗效,减轻化疗不良反应.

Objective The observation Shengrong Capsule union chemotherapy treatment to a treatment invalid non-small-cell lung cancer curative effect and the poisonous side reaction.Methods Using Shengrong Capsule to unite other commonly used chemotherapy medicine compositions the union ehemotheraPY plan to treat the non-small-cell lung cancer 68 examples to observe its curative effect and the poisonous side effect.Results Treatment group in the near future alleviating rate 89.2%,comparison group 70.1%;Symptom improvement rate:The treatment group 81.5%,the comparison group is 53.9%;The white blood cell descending rate treatment group is 29.0%,the comparison group is 41.9%;The blood platelet descending rate treatment group is 29.0%,the comparison group is 48.4%;Statistics processing has the remarkable difference(P＜0.05).Conclusion This group of materials demonstrated Shengrong Capsule joinfly to treat the non-small cell lung cancer with other chemotherapy medicines to obtain 89.2% alleviating rate,also can the obvious blood and the non-system a sanguineum poisonous side reaction,Shengrong Capsule be is effective,economical and safe.